Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Catheter-based electrical posterior box isolation (POBI) and circumferential pulmonary vein isolation (CPVI) do not improve the rhythmic outcomes of atrial fibrillation catheter ablation in previous studies with 12 to 24 months of follow-up.

Objectives: The authors analyzed the long-term rhythm outcomes of our 4 previously conducted randomized controlled trials comparing CPVI alone vs CPVI plus additional POBI using the intention-to-treat principle.

Methods: The authors analyzed 575 AF patients included in our 4 previous randomized controlled trials. We compared clinical recurrence defined as recurrent atrial arrhythmia after the index procedure. In patients who underwent a repeat procedure because of recurrence after the index procedure, the mechanism of recurrence was analyzed.

Results: After a median follow-up of 48 months, there were no significant differences in the clinical recurrence or major adverse cardiac events between the CPVI alone and CPVI plus POBI groups. The procedure time was significantly longer, and the atrial tachycardia recurrence rate was higher in the CPVI plus POBI group. In the patients who experienced clinical recurrence, there were no significant differences in the rates of cardioversion or need for repeat procedures between the groups. In patients who underwent a repeat procedure because of recurrence after the index procedure (n = 64), the pulmonary vein reconnection rate did not differ, but re-entrant atrial tachycardia was more common in the CPVI plus POBI group, while extrapulmonary vein triggers were more common in the CPVI alone group.

Conclusions: The addition of POBI to CPVI did not improve the long-term rhythm outcomes in patients undergoing atrial fibrillation catheter ablation. (The Evaluation for Prognostic Factors After Catheter Ablation of Atrial Fibrillation, NCT02138695; Evaluation of Proper Radiofrequency Catheter Ablation Strategy for the Patients Who Were Changed to Paroxysmal Atrial Fibrillation From Persistent Atrial Fibrillation, NCT02176616; Comparison of Circumferential Pulmonary Vein Isolation Alone Versus Linear Ablation in Addition to Circumferential Pulmonary Vein Isolation for Catheter Ablation in Persistent Atrial Fibrillation: Prospective Randomized Controlled Trial, NCT02721121; Comparison of Circumferential Pulmonary Vein Isolation and Complex Pulmonary Vein Isolation Additional Linear Ablation for Recurred Atrial Fibrillation After Previous Catheter Ablation: Prospective Randomized Trial [RILI Trial]; NCT02747498.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11840270PMC
http://dx.doi.org/10.1016/j.jacasi.2024.12.002DOI Listing

Publication Analysis

Top Keywords

atrial fibrillation
32
catheter ablation
28
pulmonary vein
24
vein isolation
20
circumferential pulmonary
16
fibrillation catheter
12
randomized controlled
12
clinical recurrence
12
cpvi pobi
12
atrial
11

Similar Publications

Development and external validation of a clinical prediction model for new-onset atrial fibrillation in intensive care: a multicentre, retrospective cohort study.

Lancet Digit Health

September 2025

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; NIHR Biomedical Research Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Background: New-onset atrial fibrillation, a condition associated with adverse outcomes in the short and long term, is common in patients admitted to intensive care units (ICUs). Identifying patients at high risk could inform trials of preventive interventions and help to target such interventions. We aimed to develop and externally validate a prediction model for new-onset atrial fibrillation in patients admitted to ICUs.

View Article and Find Full Text PDF

Objective: The impact of off-label underdosing of direct oral anticoagulants (DOACs) on clinical outcomes in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains unclear.

Methods: The EPIC-CAD trial (Edoxaban vs Edoxaban with antiPlatelet agent In patients with atrial fibrillation and Chronic stable Coronary Artery Disease) randomised patients with AF and stable CAD to receive either edoxaban monotherapy or dual antithrombotic therapy (edoxaban plus single antiplatelet agent). Off-label underdosing was defined as low-dose edoxaban (30 mg once daily) without standard criteria for dose reduction.

View Article and Find Full Text PDF

Background: Atrial fibrillation (AF) is the most common arrhythmia in adults, with incidence increasing with age. Cognitive impairment (CoI) and dementia share risk factors with AF. Meta-analyses indicate that AF increases the risk of CoI by 2.

View Article and Find Full Text PDF

Objective: Societal guidelines recommend vitamin K antagonists (VKAs) for atrial fibrillation patients with recent biological valve implantation, but the safety and efficacy of direct oral anticoagulants (DOACs) in this setting remain uncertain, especially in the early postoperative period. This substudy of the Left Atrial Appendage Occlusion Study (LAAOS) III trial aimed to compare thromboembolic and bleeding outcomes in patients discharged on VKAs versus DOACs after bioprosthesis implantation or mitral valve repair.

Methods: A total of 2,645 patients were included, with 461 discharged on DOACs and 2184 on VKAs.

View Article and Find Full Text PDF